---
category: news
title: "Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc."
excerpt: "Based on data found in the circulating proteome and genome, Biodesix designs tests that support treatment decisions including patient selection for immunotherapies, novel therapy combinations ... combines Biodesixâ€™s strengths in test discovery and development, artificial intelligence, and their applications to immunotherapy, with the ..."
publishedDateTime: 2020-02-11T12:22:00Z
webUrl: "https://www.businesswire.com/news/home/20200211005158/en/Biodesix-Announces-Initiation-Clinical-Phase-Biomarker-Development"
type: article
quality: 0
heat: 0
published: false

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI
  - AI in Healthcare

images:
  - url: "https://mms.businesswire.com/media/20200211005158/en/772467/23/Biodesix_r_rgb.jpg"
    width: 1200
    height: 627
    title: "Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc."

secured: "wjoSq44GR4Aj+AvNv0Mv+B3ggQ6gopD55KaAAkIVHRy2FbOoh83utvSzU5/ls8pDqaOGhE49JXCa2wiTfspFV3TavHv60LEvA6ZeT12ybNWlWmZep7a362lxFFsodw2zaYSS948nSpK3ZnMMWG+goet0ykPKYFhK+s/vooFkTV7gjsh/KtPYvG0pmgZihGGFnarU9htm9X39iMUols+X3LuR/VF3oMy1tTpqTzyUBHyohvMEwtgD8XO1ZQZdbg9VtR1OIN/RJkYJaV+W15kK/luCYum4EX+wZ052j9bTYhOuBkBaBuIAqMytYV2sE5oD;/gkuBC4KTdUPhgMVVO1QkQ=="
---

